Quick Answer
Seres Therapeutics, Inc. reported Stockholders Equity of $44.22 million for fiscal year 2025.
Seres Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $44.22M | +220.8% |
| 2024 | $13.78M | +130.7% |
| 2023 | -$44.86M | -516.0% |
| 2022 | $10.78M | -91.8% |
| 2021 | $131.51M | -24.7% |
| 2020 | $174.75M | +461.6% |
| 2019 | -$48.32M | -0.6% |
| 2018 | -$48.05M | -179.2% |
| 2017 | $60.70M | -54.2% |
| 2016 | $132.63M | -35.4% |
| 2015 | $205.39M | +868.7% |
| 2014 | -$26.72M | -140.4% |
| 2013 | -$11.12M | -155.7% |
| 2012 | -$4.35M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $43.70M | +82.7% | +32.6% |
| June 30, 2025 | $32.95M | +137.8% | -34.7% |
| March 31, 2025 | $50.47M | +184.5% | +266.1% |
| December 31, 2024 | $13.78M | +130.7% | -42.4% |
| September 30, 2024 | $23.92M | +258.2% | +127.5% |
| June 30, 2024 | -$87.07M | -485.0% | -45.8% |
| March 31, 2024 | -$59.74M | -24.8% | -33.2% |
| December 31, 2023 | -$44.86M | -516.0% | -196.6% |
- Seres Therapeutics, Inc. showed an increase of +220.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2012–2025 period, Seres Therapeutics, Inc.’s stockholders equity has grown by 1117.0% (from -$4.35 million to $44.22 million).
- The most recent figure is from Seres Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: